Skip to main content

and
Your search also matched 1 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors

Include preview-only content
  1. Article

    Open Access

    EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

    The objective of this study was to investigate real-world EGFR mutation testing in patients with metastatic non-small cell lung cancer (NSCLC) upon progression on first−/second-generation epidermal growth fact...

    Anne C. Chiang, Ancilla W. Fernandes, Melissa Pavilack, Jennifer W. Wu in BMC Cancer (2020)

  2. Article

    Open Access

    Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis

    Purine nucleoside analogs (PNAs) are the recommended first-line treatment for patients with hairy cell leukemia (HCL), but they are associated with adverse events (AEs). Due to a lack of real-world evidence re...

    Narendranath Epperla, Melissa Pavilack in Orphanet Journal of Rare Diseases (2020)

  3. Article

    Open Access

    Real-world outcomes in patients with unresected stage III non-small cell lung cancer

    This study examined real-world clinical outcomes such as progression-free survival (PFS), time to metastasis (TTM), overall survival (OS), and health-related quality of life (HRQOL) in patients with unresected...

    Kellie J. Ryan, Karen E. Skinner, Ancilla W. Fernandes in Medical Oncology (2019)

  4. Article

    Open Access

    Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants

    Palivizumab is indicated for the prevention of respiratory syncytial virus (RSV) infection in high-risk children. Previous palivizumab utilization studies examined prior authorization claims but did not examin...

    Melissa Pavilack, Robert A. Clifford, Tara Gonzales in Infectious Diseases and Therapy (2018)

  5. Article

    Open Access

    Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States

    Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States, and the risk for RSV hospitalizations is greater for infants born preterm. Recent studies in preter...

    Rohan C. Parikh, Kimmie K. McLaurin, Andrea V. Margulis in Infectious Diseases and Therapy (2017)